Association of serum copper, zinc and copper to zinc ratio in patients with acute myeloid leukemia.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc and Copper (Supplement), published as an observational study.

The present study aimed to determine the serum levels of Cu and Zn, and assess the serum Cu/Zn ratio (SCZR) in newly diagnosed adult AML cases.

Why It Was Studied

Acute myeloid leukemia (AML) is a rare hematological disorder that has detrimental effects on human health and requires the exploration of biomarkers for diagnosis and prognostic evaluation.

Essential trace elements like copper (Cu) and zinc (Zn) play diverse biological functions, however, limited data are available regarding their role in AML.

Who Took Part

The abstract describes 50 patients taking part.

PubMed indexes the participants as young adults, adults, middle-aged adults and older adults, both men and women.

What Was Measured

Acute myeloid leukemia (AML) is a rare hematological disorder that has detrimental effects on human health and requires the exploration of biomarkers for diagnosis and prognostic evaluation.

Blood samples were collected to analyze complete blood count (CBC), serum levels of Cu and Zn were determined by an atomic absorption spectrophotometer.

The subject headings attached to it are Copper, Leukemia, Myeloid, Acute, Zinc, Case-Control Studies and Prognosis.

Author keywords: Acute myeloid leukemia (AML) and Serum cu/Zn ratio (SCZR).

What This Means in Plain Language

This is an observational study of Vitamin D, K2, Magnesium and Zinc and Copper (Supplement) in 50 patients.

The publication is from 2025 (Scientific reports), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page and the Copper (Supplement) compound page, all human trials.